Patients previously diagnosed with diabetes must not have uncontrolled diabetes (defined as a hemoglobin [Hg] A1C > 7% within 28 days prior to registration)
Hemoglobin (Hb)A1c =< 7.0%
Hgb-A1C ? 7.5%;
Participants with poorly controlled diabetes defined as a hemoglobin A1c (HgbA1c) >= 7.0%
Hgb-A1C =< 7.5%
Hemoglobin A1c < 7%
Glycosylated hemoglobin (Hgb A1c) =< 6.5%
Glycated hemoglobin (Hgb-A1C) level of =< 7.5%.
Abnormal complete blood count, comprehensive metabolic panel, urine, hemoglobin (Hgb) A1c (study physician discretion)
Hemoglobin A1C < 6.5%, within 2 weeks of registration
Poorly controlled diabetes defined by hemoglobin A1C > 9.0 at screening.
Uncontrolled diabetes (defined as Hgb A1C > 8.0%)
Within 14 days of subject registration: Hemoglobin (HB)A1c =< 8%
History of peripheral vascular disease (PVD) that has required surgical or percutaneous intervention or documented PVD that requires medical management with medications such as acetylsalicylic acid (ASA) + clopidogrel; patients with diabetes that is not well controlled are excluded from participation; not well controlled is defined as a hemoglobin (Hgb) A1C of greater than 7.5%
Patients must not have uncontrolled diabetes mellitus (defined by a hemoglobin [Hgb] A1c > 8) obtained within 14 days prior to registration; optimal glucose control (Hgb A1c =< 8) must be achieved before registration and monitored during protocol treatment
Severe and/or uncontrolled medical disease, including: \r\n* Uncontrolled diabetes mellitus (hemoglobin A1c [A1c] > 8) \r\n* Chronic kidney disease stage III or higher (creatinine clearance < 60 mL/min/m^2 by Modified Diet in Renal Disease [MDRD] calculation) \r\n* Active, uncontrolled infection
Diabetes mellitus with poor glycemic control (documented hemoglobin A1c > 7% within 4 weeks prior to study entry)
Hemoglobin A1c =< 9%
Glycosylated hemoglobin (Hgb A1C) > 8.0%
Has a history of autoimmune disorders, including uncontrolled diabetes (\uncontrolled\ defined as Hemoglobin A1c ? 9% in 28 days prior to study).
Uncontrolled diabetes mellitus as defined by hemoglobin (Hb)A1c > 7% within 28 days prior to registration despite adequate therapy
Hemoglobin (Hgb) A1C =< 8%
Uncontrolled diabetes defined as a hemoglobin A1C level > 8% (therapeutic action is indicated at greater than 8%)
Obtained within 2 weeks from study entry: Hemoglobin A1c (HgBA1c) =< 8%
Have poorly controlled diabetes (hemoglobin [HgB] A1C >= 8%)
Poorly controlled diabetes (hemoglobin [Hgb] A1C > 9)
Hemoglobin (Hgb) A1C =< 8%
Uncontrolled diabetes defined as a hemoglobin A1C level > 8% (therapeutic action is indicated at greater than 8%)
Hemoglobin (Hgb) A1C =< 8%
Uncontrolled diabetes defined as a hemoglobin A1C level > 8% (therapeutic action is indicated at greater than 8%)
Patient received previous treatment with oral AC480
For patients with diabetes, hemoglobin A1C test must have been performed =< 90 days prior to registration
Hemoglobin A1c > 7.5% or diabetes requiring insulin therapy
Participants must have no uncontrolled diabetes mellitus defined as glycosylated hemoglobin (Hgb A1C) > 7%
Subjects who have diabetes with a hemoglobin (Hgb) A1c > 7
Glycosylated hemoglobin (Hb A1c) =< 7%
Poorly controlled diabetes (hemoglobin A1c [Hgb A1C] > 9 or random blood glucose > 250 mg/dL)
Patients with hemoglobin a1c > 6.3 or who are being actively treated for diabetes
Hemoglobin A1C > 8.5%
Participants with known uncontrolled diabetes, defined as a hemoglobin A1C of > 8%
